Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis: Dawnzera Approval Kicks Off New Era For Strikingly Undervalued Pharma
03:50pm, Tuesday, 26'th Aug 2025
Ionis Pharmaceuticals remains a Buy after Dawnzera's FDA approval, which strengthens its pipeline and revenue outlook despite a history of operating losses. Dawnzera's market opportunity in hereditary
US FDA approves Ionis' drug for rare genetic disorder
11:58am, Thursday, 21'st Aug 2025
The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic disorder.
DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema
11:45am, Thursday, 21'st Aug 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has approved DAWNZERA™ (donidalorsen) for prophylaxis t
Ionis (IONS) Q2 Revenue Soars 101%
12:37pm, Thursday, 31'st Jul 2025
Ionis Pharmaceuticals (IONS -0.44%), a biotechnology company focused on RNA-targeted therapeutics, reported its second quarter 2025 earnings on July 30, 2025. The headline news was a substantial beat
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
10:11am, Thursday, 31'st Jul 2025
Ionis crushes Q2 estimates with EPS of $0.86 and sales of $452 million, lifting its 2025 revenue forecast and sending shares up 5%.
Ionis Pharmaceuticals, Inc. (IONS) Q2 2025 Earnings Call Transcript
04:42pm, Wednesday, 30'th Jul 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q2 2025 Earnings Conference Call July 30, 2025 11:30 AM ET Company Participants Brett P. Monia - Founder, CEO & Director D.
Ionis Posts Surprise Q2 Profit, Double Revenues On Stronger Sales From Newly Approved Genetic Disease Drug
02:34pm, Wednesday, 30'th Jul 2025
Ionis Pharmaceuticals Inc. IONS reported second-quarter adjusted earnings of 85 cents on Wednesday. The company reported an adjusted loss of $35 million a year ago.
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
10:31am, Wednesday, 30'th Jul 2025
While the top- and bottom-line numbers for Ionis Pharmaceuticals (IONS) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metr
Ionis Pharmaceuticals (IONS) Q2 Earnings and Revenues Beat Estimates
09:11am, Wednesday, 30'th Jul 2025
Ionis Pharmaceuticals (IONS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to a loss of $0.45 per share a year ago.
Ionis reports second quarter 2025 financial results and highlights progress on key programs
07:00am, Wednesday, 30'th Jul 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the second quarter ended June 30, 2025.
TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for familial chylomicronemia syndrome (FCS)
07:15am, Friday, 25'th Jul 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Sobi® today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency
Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy?
11:06am, Wednesday, 23'rd Jul 2025
Ionis Pharmaceuticals (IONS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases
07:41am, Wednesday, 23'rd Jul 2025
Stanley Crooke, Ionis Pharmaceuticals founder and n-Lorem founder, joins 'Squawk Box' to discuss the fight against rare diseases, the development of ASO technology, and more.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that positive results from the Phase 3 OASISplus prospective switch study of donidalorsen in patients with
Ionis to hold second quarter 2025 financial results webcast
07:05am, Wednesday, 16'th Jul 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, July 30th at 11:30 a.m. Eastern Time to discuss its second
